Genetic products differentially expressed in tumors and the use thereof

Abstract

According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.

1 - 101 . (canceled) 
     
     
         102 . A method of treating a disease characterized by expression of a tumor-associated antigen that (a) is encoded by a nucleic acid which comprises a nucleic acid sequence of SEQ ID NO: 7 or (b) comprises the amino acid sequence of SEQ ID NO: 16, comprising administering to a patient suffering from said disease an antibody that selectively binds to the tumor-associated antigen, wherein said disease is a pancreatic tumor, a gastric tumor or a tumor of the stomach. 
     
     
         103 . The method according to  claim 102 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a combination of any of the foregoing, and an immunoreactive fragment of any of the foregoing. 
     
     
         104 . The method according to  claim 102 , wherein the antibody is coupled to a therapeutic agent. 
     
     
         105 . The method according to  claim 104 , wherein the therapeutic agent is an anticancer agent, a toxin, a radioactive compound or a cytostatic or cytolytic compound. 
     
     
         106 . The method according to  claim 102 , wherein the binding of the antibody causes a cytolytic reaction and/or induces cytokine release. 
     
     
         107 . The method according to  claim 102 , wherein the tumor of the pancreas is an adenocarcinoma of the pancreas. 
     
     
         108 . The method according to  claim 102 , wherein the tumor of the stomach is an adenocarcinoma of the stomach or a gastric adenocarcinoma. 
     
     
         109 . A method of treating a pancreatic tumor, a gastric tumor or a tumor of the stomach in a patient, comprising administering to the patient a monoclonal antibody that selectively binds to a tumor-associated antigen that (a) is encoded by a nucleic acid which comprises a nucleic acid sequence of SEQ ID NO: 7 or (b) comprises the amino acid sequence of SEQ ID NO: 16; wherein the tumor-associated antigen is expressed in the pancreatic tumor, the gastric tumor or the tumor of the stomach. 
     
     
         110 . The method according to  claim 109 , wherein the antibody is coupled to a therapeutic agent. 
     
     
         111 . The method according to  claim 110 , wherein the therapeutic agent is an anticancer agent, a toxin, a radioactive compound or a cytostatic or cytolytic compound. 
     
     
         112 . The method according to  claim 109 , wherein the binding of the agent causes a cytolytic reaction and/or induces cytokine release. 
     
     
         113 . The method according to  claim 109 , wherein the tumor of the pancreas is an adenocarcinoma of the pancreas. 
     
     
         114 . The method according to  claim 109 , wherein the tumor of the stomach is an adenocarcinoma of the stomach or a gastric adenocarcinoma. 
     
     
         115 . A method of treating adenocarcinoma in a patient, comprising administering to the patient a chimeric monoclonal antibody that selectively binds to a tumor-associated antigen that (a) is encoded by a nucleic acid which comprises a nucleic acid sequence of SEQ ID NO: 7 or (b) comprises the amino acid sequence of SEQ ID NO: 16; wherein the adenocarcinoma is adenocarcinoma of the stomach or gastric adenocarcinoma. 
     
     
         116 . The method according to  claim 115 , wherein the antibody is coupled to a therapeutic agent. 
     
     
         117 . The method according to  claim 116 , wherein the therapeutic agent is an anticancer agent, a toxin, a radioactive compound or a cytostatic or cytolytic compound. 
     
     
         118 . The method according to  claim 115 , wherein the binding of the antibody causes a cytolytic reaction and/or induces cytokine release.